A use of shikonian acid for reversing drug resistance of ovarian cancer to paclitaxel

A technology for ovarian cancer and drug resistance, applied in the field of medicine, can solve the problems of high mortality and high recurrence rate of the disease
CN109223746BActive Publication Date: 2020-12-18菅金泒
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Patents(China)
Current Assignee / Owner
菅金泒
Publication Date
2020-12-18

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The invention discloses use of lacca acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and thesurvival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinumand paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention discloses that lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and canbe developed as a medicine for reversing the resistance of ovarian cancer to taxol. The invention is characterized in that the lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of medicine and relates to the discovery of drugs for reversing drug resistance of ovarian cancer to paclitaxel. Background technique

[0002] Ovarian cancer is one of the three major malignant tumors of the female reproductive system, and the survival time of most advanced ovarian cancer patients is less than 5 years. The clinical treatment of ovarian cancer usually uses tumor cytoreductive surgery, supplemented by chemotherapy with platinum and paclitaxel after surgery. However, the drug resistance of ovarian cancer cells to chemotherapeutic drugs leads to a high recurrence rate and high mortality rate of the disease, which has become a bottleneck in clinical treatment. Contents of the invention

[0003] The purpose of the present invention is to provide a drug for reversing drug resistance of ovarian cancer to paclitaxel.

[0004] The present invention realizes through following technical scheme:

[0005] Appl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More